Loading
A phase 2 trial of Alcestobart run by BeiGene, completed.
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05577702 by BeiGene, with 121 participants enrolled, started 2023-03-08. Conditions recorded: Non Small Cell Lung Cancer. Interventions recorded: Tislelizumab, Ociperlimab, Alcestobart, Cisplatin, Carboplatin, Pemetrexed and Paclitaxel.
Shares Alcestobart, Nanjing Leads Biolabs, Non-small-cell lung cancer and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/